An excellent example is the N2M2 study in patients with newly diagnosed glioblastoma without methylation of the O6-methylguanine-DNA methyltransferase (MGMT) promoter, a phase I/IIa umbrella trial of molecularly matched targeted therapies [17]. The gene discussed is MGMT; the disease is glioblastoma.